AI Insight
Researchers analyzing Fitbit data found that people taking GLP-1 receptor agonist medications for weight loss, including Ozempic, Wegovy, Mounjaro, and Zepbound, experienced significant reductions in daily step counts and overall exercise levels after starting treatment. This decline in physical activity occurred even as participants successfully lost weight. The findings raise concerns because these medications can reduce muscle mass alongside fat loss, and decreased physical activity may further compromise muscle preservation and long-term health outcomes.
Why it matters
This research suggests that weight loss from GLP-1 medications alone may not provide the full health benefits expected if physical activity declines simultaneously. Patients and healthcare providers may need to implement specific strategies to maintain or increase exercise during treatment to preserve muscle mass and optimize metabolic health.
Understand the Science
People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily step counts and exercise levels dropped after people started these medications, despite successful weight loss. Because the drugs can reduce muscle mass along with fat, the decline in physical activity raises concerns about preserving strength and long-term health.
Source: People taking GLP-1 weight loss drugs like Ozempic started moving less